STOCK TITAN
  1. Home
  2. News
  3. ATRA

Atara Biotherapeutics, Inc - ATRA STOCK NEWS

Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.

Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.

The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:

  • Pinta 745
  • STM 434
  • ATA 842

Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:

  • Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
  • Cytomegalovirus (CMV)-targeted CTLs
  • Wilms Tumor 1 (WT1)-targeted CTLs

These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.

Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.

The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.

Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.

News

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. The data supports ATA3431's advancement into clinical testing for the treatment of B-cell malignancies, with promising results compared to an autologous CAR-T benchmark. The company is excited about the potential of ATA3431 and looks forward to evaluating it in the clinic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
clinical trial
-
News

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) reported the grant of 27,000 restricted stock units to three new employees under the 2018 Inducement Plan. The units vest over four years, subject to continuous employment. This move aims to attract and retain talent, aligning employee interests with company growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
none
-
News

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Rhea-AI Summary
Atara Biotherapeutics, a leader in T-cell immunotherapy, announced positive data for tabelecleucel (tab-cel® or EBVALLO™) in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system. The multicohort Phase 2 EBVision trial showed a 77.8% objective response rate in 18 patients, with a favorable safety profile. The estimated one-year overall survival rate was 70.6% for all patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
conferences clinical trial
News

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) to participate in fireside chat at Evercore ISI HealthCONx Conference. Pascal Touchon, President and CEO, to present at 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023, at 10:50 a.m. EST. Webcast available on atarabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.99%
Tags
conferences
-
News

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at Stifel Healthcare Conference on November 14, 2023, discussing T-cell immunotherapy and EBV T-cell platform. Pascal Touchon, President and CEO, to participate in a fireside chat at 8:30 a.m. PST / 11:30 a.m. EST. Webcast available on atarabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
conferences
-
News

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announces the disappointing results of its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS), failing to meet the primary endpoint of confirmed disability improvement (CDI). Despite this setback, the company remains optimistic about its allogeneic CAR-T portfolio and plans to focus resources on advancing this pipeline, while also reducing expenses and extending its cash runway beyond Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-80.17%
Tags
clinical trial
News

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Rhea-AI Summary
Atara Biotherapeutics reports expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel®), financial results for Q3 2023, and upcoming catalysts. The partnership includes up to $640 million in payments, double-digit tiered royalties, and funding of tab-cel global development costs. Atara is restructuring to reduce expenses and extend cash runway. ATA188 Phase 2 EMBOLD study analysis on track for early November. Atara will focus on ATA188 and allogeneic CAR-T programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
partnership earnings
-
News

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Atara Biotherapeutics reports grant of restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
none
-
News

Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability

Rhea-AI Summary
Atara Biotherapeutics reports progress in regulatory pathway for tabelecleucel, expects to submit BLA in Q2 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
earnings
News

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Atara Biotherapeutics grants 3,250 restricted stock units to a newly hired employee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none

FAQ

What is the current stock price of Atara Biotherapeutics (ATRA)?

The current stock price of Atara Biotherapeutics (ATRA) is $11.47 as of November 22, 2024.

What is the market cap of Atara Biotherapeutics (ATRA)?

The market cap of Atara Biotherapeutics (ATRA) is approximately 64.3M.

What does Atara Biotherapeutics, Inc specialize in?

Atara Biotherapeutics specializes in developing transformative therapies for serious diseases including cancer, kidney disease, and autoimmune disorders.

When was Atara Biotherapeutics founded?

Atara Biotherapeutics was founded in August 2012.

Who is Atara Ciechanover?

Atara Ciechanover is the namesake of the company, who suffered from cancer before passing away in 2012.

What are some of Atara's key product candidates?

Some of Atara's key product candidates include Pinta 745, STM 434, ATA 842, Tab-cel, ATA188, and ATA3219 (CAR T platform).

With which institution is Atara Biotherapeutics collaborating?

Atara Biotherapeutics is collaborating with Memorial Sloan Kettering Cancer Center (MSK).

What types of T-cell therapies is Atara developing?

Atara is developing T-cell therapies targeting Epstein-Barr Virus (EBV)-targeted CTLs, Cytomegalovirus (CMV)-targeted CTLs, and Wilms Tumor 1 (WT1)-targeted CTLs.

What is the mission of Atara Biotherapeutics?

Atara Biotherapeutics aims to provide better treatment options for patients, altering the course of disease progression through innovative therapies.

Where does Atara Biotherapeutics operate?

Atara Biotherapeutics operates in the United States healthcare sector.

What are activin and myostatin in the context of Atara's research?

Activin and myostatin are growth factors that Atara's research has shown can change the course of disease progression.

How does Atara manage its business operations?

Atara manages its business as one operating and reportable segment focusing on developing therapeutics.

Stock ATRA logo
Atara Biotherapeutics, Inc

Nasdaq:ATRA

ATRA Rankings

#4697 Ranked by Market Cap
N/A Ranked by Dividends

ATRA Stock Data

64.28M
4.47M
22.15%
50.83%
11.21%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS